Related Experiment Videos

Idiopathic infantile hypercalcemia discovered in the newborn period

H Shimizu1, S Kodama, A Takeuchi

  • 1Department of Pediatrics, Himeji Red Cross Hospital, Japan.

Acta Paediatrica Japonica : Overseas Edition
|December 1, 1994
PubMed

Insights

Idiopathic infantile hypercalcemia (IIH) in a newborn was treated effectively with calcitonin, reducing high serum 1,25-dihydroxyvitamin D3 levels. This suggests elevated 1,25(OH)2D3 contributes to IIH pathogenesis.

Area of Science:

  • Pediatric Endocrinology
  • Nephrology
  • Genetics

Background:

  • Idiopathic infantile hypercalcemia (IIH) presents with hypercalcemia, hypercalciuria, distinctive facial features, and nephrocalcinosis.
  • The exact pathogenesis of IIH, particularly the source of elevated 1,25-dihydroxyvitamin D3 (1,25[OH]2D3), remains unclear.

Observation:

  • A male newborn with typical IIH signs was managed without Vitamin D3 supplementation.
  • Treatment involved a vitamin D-free, low-calcium diet and rectal calcitonin (elcatonin).

Findings:

  • Rectal calcitonin demonstrated significant efficacy in managing IIH symptoms.
  • Serum calcium normalized, and serum 1,25(OH)2D3 levels decreased from 101.5 to 75.6 pg/mL following treatment.

Implications:

  • High serum 1,25(OH)2D3 concentration appears to be a key factor in the pathogenesis of IIH.
  • Further research is needed to elucidate the mechanisms driving elevated 1,25(OH)2D3 in IIH.

Related Concept Videos